Exelixis Bcr-Abl inhibitor shows efficacy in CML

Phase I data presented at the European Hematology Association (EHA) meeting shows Exelixis’ Bcr-Abl inhibitor XL-228 to demonstrate efficacy in patients with chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ALL).

Supergens PIM kinase inhibitor SGI-1776 active in vivo

Data presented at the European Hematology Association (EHA) meeting shows SuperGen’s PIM Kinase Inhibitor  SGI-1776 to cause tumor regression in acute myologenous leukemia (AML) xenograft models

Pfizer present data on CP-751,871 in NSCLC

Data presented at ASCO show Pfizer’s IGF-R1MAb CP-751,871 to demonstrate efficacy in non-small cell lung cancer (NSCLC) and Ewing’s Sarcoma. In NSCLC Phase II data showed that 54 percent of patients with Stage III/IV treatment-naïve NSCLC demonstrated an objective response [...]

High initial dose of Gleevec results in better early responses in CML

New phase III data shows that when Gleevec is administered at a high initial dose (800 mg/day) there is a faster achievement of clinical milestones. The study did not however, meet its primary endpoint at 1 year